{"id":63386,"date":"2017-04-07T11:08:47","date_gmt":"2017-04-07T11:08:47","guid":{"rendered":"https:\/\/leitat.org\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/"},"modified":"2025-02-10T11:23:57","modified_gmt":"2025-02-10T11:23:57","slug":"actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos","status":"publish","type":"post","link":"https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/","title":{"rendered":"Actividad anti-tumoral y antimetast\u00e1sica en modelos animales de c\u00e1nceres humanos"},"content":{"rendered":"\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

La efectividad limitada de los tratamientos aprobados, as\u00ed como las evidencias de sus resistencias y toxicidades, enfatizan la necesidad del desarrollo de nuevos anticuerpos monoclonales terap\u00e9uticos para mejorar la eficacia en los tratamientos de met\u00e1stasis de tumores en mama o p\u00e1ncreas, o en tumores hematol\u00f3gicos (leucemias y linfomas).<\/p>

Durante la anualidad 2016 de este proyecto se ha estado trabajando en los siguientes objetivos claramente definidos y diferenciados:<\/p>

    • FIBHULP ha constatado en experimentos in vitro que el anticuerpo monoclonal contra CCR7 es eficaz en un gran n\u00famero de leucemias y linfomas.<\/li><\/ul><\/li><\/ul>
        • IMMED ha empezado el desarrollo de modelos animales de aquellas enfermedades en las que FIBHULP ha demostrado eficacia del anticuerpo monoclonal contra CCR7.<\/li><\/ul><\/li><\/ul>
          • Leitat ha llevado a cabo la selecci\u00f3n de l\u00edneas tumorales para realizar los estudios de eficacia con los anticuerpos monoclonales contra S100A4, S100P y S100A7 as\u00ed como la producci\u00f3n de la cantidad necesaria de anticuerpo contra las tres prote\u00ednas, paso previo a los estudios funcionales in vitro (en marcha) e in vivo.<\/li><\/ul>

            El consorcio que lo est\u00e1 llevando a cabo est\u00e1 formado por una empresa, Immunological and Medicinal Products (IMMED) y dos centros de reconocido prestigio internacional: la Fundaci\u00f3n para la Investigaci\u00f3n Biom\u00e9dica del Hospital Universitario de la Princesa (FIBHULP) y el centro tecnol\u00f3gico Leitat. IMMED es una empresa con amplia experiencia en el desarrollo de terapias y m\u00e9todos de diagn\u00f3stico molecular para oncolog\u00eda y enfermedades inflamatorias y autoinmunes. IMMED participar\u00e1 en la validaci\u00f3n pre-cl\u00ednica y funcional de los anticuerpos leads. El centro FIBHULP participar\u00e1 en los ensayos in vitro de la uni\u00f3n de los anticuerpos y Leitat participar\u00e1 en determinar la eficacia de la actividad de los anticuerpos en l\u00edneas celulares y la determinaci\u00f3n de la actividad antiangiog\u00e9nica y antimetast\u00e1sica en modelos animales in vivo. Se espera que esta estrategia mejore la eficacia de los tratamientos de met\u00e1stasis de tumores en mama o p\u00e1ncreas.<\/p>

            El proyecto, con n\u00famero de expediente RTC-2015-3318-1, aprobado en la Convocatoria 2015 del Programa Estatal de I+D+i, orientada a los Retos de la Sociedad, ha sido financiado por el Ministerio de Econom\u00eda, Industria y Competitividad, y cofinanciado a trav\u00e9s de fondos FEDER de UNION EUROPEA con el objetivo principal de Promover el desarrollo tecnol\u00f3gico, la innovaci\u00f3n y una investigaci\u00f3n de calidad.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t

            \n\t\t\t\t\t\t
            \n\t\t\t\t\t
            \n\t\t\t
            \n\t\t\t\t\t\t
            \n\t\t\t\t
            \n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t
            \n\t\t\t\t
            \n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\"\"\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t
            \n\t\t\t
            \n\t\t\t\t\t\t
            \n\t\t\t\t
            \n\t\t\t\t\t\t\t\t\t

            Financiado por: FEDER\/Ministerio de Ciencia,Innovaci\u00f3n y Universidades \u2013 Agencia Estatal de Investigaci\u00f3n\/_Proyecto RTC-2015-3318-1<\/p>

            Objetivo Tem\u00e1tico del Programa Operativo: Promover el desarrollo tecnol\u00f3gico, la innovaci\u00f3n y una investigaci\u00f3n de calidad.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t<\/section>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

            La efectividad limitada de los tratamientos aprobados, as\u00ed como las evidencias de sus resistencias y toxicidades, enfatizan la necesidad del desarrollo de nuevos anticuerpos monoclonales terap\u00e9uticos para mejorar la eficacia en los tratamientos de met\u00e1stasis de tumores en mama o p\u00e1ncreas, o en tumores hematol\u00f3gicos (leucemias y linfomas). Durante la anualidad 2016 de este proyecto […]<\/p>\n","protected":false},"author":3,"featured_media":46953,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[142],"tags":[],"class_list":["post-63386","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-health-technologies-en"],"yoast_head":"\nMETASTASIS: Actividad anti-tumoral y antimetast\u00c3\u00a1sica de anticuerpos monoclonales en modelos animales de c\u00c3\u00a1nceres humanos<\/title>\n<meta name=\"description\" content=\"METASTASIS: Actividad anti-tumoral y antimetast\u00c3\u00a1sica de anticuerpos monoclonales en modelos animales de c\u00c3\u00a1nceres humanos. Un proyecto RETOS COLABORACI\u00c3\u201cN\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"METASTASIS: Actividad anti-tumoral y antimetast\u00c3\u00a1sica de anticuerpos monoclonales en modelos animales de c\u00c3\u00a1nceres humanos\" \/>\n<meta property=\"og:description\" content=\"METASTASIS: Actividad anti-tumoral y antimetast\u00c3\u00a1sica de anticuerpos monoclonales en modelos animales de c\u00c3\u00a1nceres humanos. Un proyecto RETOS COLABORACI\u00c3\u201cN\" \/>\n<meta property=\"og:url\" content=\"https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/\" \/>\n<meta property=\"og:site_name\" content=\"Leitat Technological Center\" \/>\n<meta property=\"article:published_time\" content=\"2017-04-07T11:08:47+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-02-10T11:23:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/leitat.org\/wp-content\/uploads\/2017\/04\/255px-Anticuerpo.svg_.png\" \/>\n\t<meta property=\"og:image:width\" content=\"255\" \/>\n\t<meta property=\"og:image:height\" content=\"360\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Comunicaci\u00f3n Leitat\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Comunicaci\u00f3n Leitat\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/\"},\"author\":{\"name\":\"Comunicaci\u00f3n Leitat\",\"@id\":\"https:\/\/leitat.org\/en\/#\/schema\/person\/ca8dc97489cd821df9e0c42930e89131\"},\"headline\":\"Actividad anti-tumoral y antimetast\u00e1sica en modelos animales de c\u00e1nceres humanos\",\"datePublished\":\"2017-04-07T11:08:47+00:00\",\"dateModified\":\"2025-02-10T11:23:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/\"},\"wordCount\":456,\"publisher\":{\"@id\":\"https:\/\/leitat.org\/en\/#organization\"},\"image\":{\"@id\":\"https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/leitat.org\/wp-content\/uploads\/2017\/04\/255px-Anticuerpo.svg_.png\",\"articleSection\":[\"Health technologies\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/\",\"url\":\"https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/\",\"name\":\"METASTASIS: Actividad anti-tumoral y antimetast\u00c3\u00a1sica de anticuerpos monoclonales en modelos animales de c\u00c3\u00a1nceres humanos\",\"isPartOf\":{\"@id\":\"https:\/\/leitat.org\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/leitat.org\/wp-content\/uploads\/2017\/04\/255px-Anticuerpo.svg_.png\",\"datePublished\":\"2017-04-07T11:08:47+00:00\",\"dateModified\":\"2025-02-10T11:23:57+00:00\",\"description\":\"METASTASIS: Actividad anti-tumoral y antimetast\u00c3\u00a1sica de anticuerpos monoclonales en modelos animales de c\u00c3\u00a1nceres humanos. Un proyecto RETOS COLABORACI\u00c3\u201cN\",\"breadcrumb\":{\"@id\":\"https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/#primaryimage\",\"url\":\"https:\/\/leitat.org\/wp-content\/uploads\/2017\/04\/255px-Anticuerpo.svg_.png\",\"contentUrl\":\"https:\/\/leitat.org\/wp-content\/uploads\/2017\/04\/255px-Anticuerpo.svg_.png\",\"width\":255,\"height\":360},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"HOME\",\"item\":\"https:\/\/leitat.org\/en\/home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Health technologies\",\"item\":\"https:\/\/leitat.org\/en\/blog\/category\/health-technologies-en\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Actividad anti-tumoral y antimetast\u00e1sica en modelos animales de c\u00e1nceres humanos\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/leitat.org\/en\/#website\",\"url\":\"https:\/\/leitat.org\/en\/\",\"name\":\"Leitat Technological Center\",\"description\":\"Managing Technologies\",\"publisher\":{\"@id\":\"https:\/\/leitat.org\/en\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/leitat.org\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/leitat.org\/en\/#organization\",\"name\":\"Leitat Technological Center\",\"url\":\"https:\/\/leitat.org\/en\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/leitat.org\/en\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/leitat.org\/wp-content\/uploads\/2024\/10\/logo-leitat.svg\",\"contentUrl\":\"https:\/\/leitat.org\/wp-content\/uploads\/2024\/10\/logo-leitat.svg\",\"width\":226,\"height\":78,\"caption\":\"Leitat Technological Center\"},\"image\":{\"@id\":\"https:\/\/leitat.org\/en\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/leitat.org\/en\/#\/schema\/person\/ca8dc97489cd821df9e0c42930e89131\",\"name\":\"Comunicaci\u00f3n Leitat\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/ce5e10560c8753dc6a31f108c84f08103b3e4bb78f97dde95a1445d45abbb09a?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/ce5e10560c8753dc6a31f108c84f08103b3e4bb78f97dde95a1445d45abbb09a?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/ce5e10560c8753dc6a31f108c84f08103b3e4bb78f97dde95a1445d45abbb09a?s=96&d=mm&r=g\",\"caption\":\"Comunicaci\u00f3n Leitat\"},\"sameAs\":[\"https:\/\/leitat.org\"],\"url\":\"https:\/\/leitat.org\/en\/blog\/author\/comunica-wp\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"METASTASIS: Actividad anti-tumoral y antimetast\u00c3\u00a1sica de anticuerpos monoclonales en modelos animales de c\u00c3\u00a1nceres humanos","description":"METASTASIS: Actividad anti-tumoral y antimetast\u00c3\u00a1sica de anticuerpos monoclonales en modelos animales de c\u00c3\u00a1nceres humanos. Un proyecto RETOS COLABORACI\u00c3\u201cN","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"METASTASIS: Actividad anti-tumoral y antimetast\u00c3\u00a1sica de anticuerpos monoclonales en modelos animales de c\u00c3\u00a1nceres humanos","og_description":"METASTASIS: Actividad anti-tumoral y antimetast\u00c3\u00a1sica de anticuerpos monoclonales en modelos animales de c\u00c3\u00a1nceres humanos. Un proyecto RETOS COLABORACI\u00c3\u201cN","og_url":"https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/","og_site_name":"Leitat Technological Center","article_published_time":"2017-04-07T11:08:47+00:00","article_modified_time":"2025-02-10T11:23:57+00:00","og_image":[{"width":255,"height":360,"url":"https:\/\/leitat.org\/wp-content\/uploads\/2017\/04\/255px-Anticuerpo.svg_.png","type":"image\/png"}],"author":"Comunicaci\u00f3n Leitat","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Comunicaci\u00f3n Leitat","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/#article","isPartOf":{"@id":"https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/"},"author":{"name":"Comunicaci\u00f3n Leitat","@id":"https:\/\/leitat.org\/en\/#\/schema\/person\/ca8dc97489cd821df9e0c42930e89131"},"headline":"Actividad anti-tumoral y antimetast\u00e1sica en modelos animales de c\u00e1nceres humanos","datePublished":"2017-04-07T11:08:47+00:00","dateModified":"2025-02-10T11:23:57+00:00","mainEntityOfPage":{"@id":"https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/"},"wordCount":456,"publisher":{"@id":"https:\/\/leitat.org\/en\/#organization"},"image":{"@id":"https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/#primaryimage"},"thumbnailUrl":"https:\/\/leitat.org\/wp-content\/uploads\/2017\/04\/255px-Anticuerpo.svg_.png","articleSection":["Health technologies"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/","url":"https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/","name":"METASTASIS: Actividad anti-tumoral y antimetast\u00c3\u00a1sica de anticuerpos monoclonales en modelos animales de c\u00c3\u00a1nceres humanos","isPartOf":{"@id":"https:\/\/leitat.org\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/#primaryimage"},"image":{"@id":"https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/#primaryimage"},"thumbnailUrl":"https:\/\/leitat.org\/wp-content\/uploads\/2017\/04\/255px-Anticuerpo.svg_.png","datePublished":"2017-04-07T11:08:47+00:00","dateModified":"2025-02-10T11:23:57+00:00","description":"METASTASIS: Actividad anti-tumoral y antimetast\u00c3\u00a1sica de anticuerpos monoclonales en modelos animales de c\u00c3\u00a1nceres humanos. Un proyecto RETOS COLABORACI\u00c3\u201cN","breadcrumb":{"@id":"https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/#primaryimage","url":"https:\/\/leitat.org\/wp-content\/uploads\/2017\/04\/255px-Anticuerpo.svg_.png","contentUrl":"https:\/\/leitat.org\/wp-content\/uploads\/2017\/04\/255px-Anticuerpo.svg_.png","width":255,"height":360},{"@type":"BreadcrumbList","@id":"https:\/\/leitat.org\/en\/blog\/actividad-anti-tumoral-y-antimetastasica-de-anticuerpos-monoclonales-en-modelos-animales-de-canceres-humanos\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"HOME","item":"https:\/\/leitat.org\/en\/home\/"},{"@type":"ListItem","position":2,"name":"Health technologies","item":"https:\/\/leitat.org\/en\/blog\/category\/health-technologies-en\/"},{"@type":"ListItem","position":3,"name":"Actividad anti-tumoral y antimetast\u00e1sica en modelos animales de c\u00e1nceres humanos"}]},{"@type":"WebSite","@id":"https:\/\/leitat.org\/en\/#website","url":"https:\/\/leitat.org\/en\/","name":"Leitat Technological Center","description":"Managing Technologies","publisher":{"@id":"https:\/\/leitat.org\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/leitat.org\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/leitat.org\/en\/#organization","name":"Leitat Technological Center","url":"https:\/\/leitat.org\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/leitat.org\/en\/#\/schema\/logo\/image\/","url":"https:\/\/leitat.org\/wp-content\/uploads\/2024\/10\/logo-leitat.svg","contentUrl":"https:\/\/leitat.org\/wp-content\/uploads\/2024\/10\/logo-leitat.svg","width":226,"height":78,"caption":"Leitat Technological Center"},"image":{"@id":"https:\/\/leitat.org\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/leitat.org\/en\/#\/schema\/person\/ca8dc97489cd821df9e0c42930e89131","name":"Comunicaci\u00f3n Leitat","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/ce5e10560c8753dc6a31f108c84f08103b3e4bb78f97dde95a1445d45abbb09a?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/ce5e10560c8753dc6a31f108c84f08103b3e4bb78f97dde95a1445d45abbb09a?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/ce5e10560c8753dc6a31f108c84f08103b3e4bb78f97dde95a1445d45abbb09a?s=96&d=mm&r=g","caption":"Comunicaci\u00f3n Leitat"},"sameAs":["https:\/\/leitat.org"],"url":"https:\/\/leitat.org\/en\/blog\/author\/comunica-wp\/"}]}},"_links":{"self":[{"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/posts\/63386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/comments?post=63386"}],"version-history":[{"count":1,"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/posts\/63386\/revisions"}],"predecessor-version":[{"id":63436,"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/posts\/63386\/revisions\/63436"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/media\/46953"}],"wp:attachment":[{"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/media?parent=63386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/categories?post=63386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/leitat.org\/en\/wp-json\/wp\/v2\/tags?post=63386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}